Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopamine and norepinephrine blockade in human cost-benefit learning
NL-OMON52086Active, not recruiting
- Sponsor
- Department of Psychiatry
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of haloperidol and propranolol (2 arms), sponsored by Department of Psychiatry. Primary endpoint: Task performance on two cost-benefit evaluation tasks. Started May 2021; status: active, not recruiting.
02
Drugs
haloperidolpropranolol
Beyond the preview
Go deeper on NL-OMON52086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52086.